Skip directly to local search Skip directly to A to Z list Skip directly to navigation Skip directly to site content Skip directly to page options
CDC Home

Volume 18, Number 1—January 2012

Research

Modeling Insights into Haemophilus influenzae Type b Disease, Transmission, and Vaccine Programs

Michael L. Jackson1Comments to Author , Charles E. Rose, Amanda Cohn, Fatima Coronado, Thomas A. Clark, Jay D. Wenger, Lisa Bulkow, Michael G. Bruce, Nancy E. Messonnier, and Thomas W. Hennessy
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA

Main Article

Figure 3

Figure 3. Predicted effects of extended Haemophilus influenzae type b (Hib) vaccine shortage on the incidence of invasive Hib disease in the United States (A) and of switching from PRP-OMP to PRP-T vaccine in the Alaska Native population (B). See text for complete description of shortage scenarios. PRP-OMP, Hib polyribosylribitol phosphate polysaccharide conjugated to Neisseria meningitidis outer membrane protein; PRP-T, polyribosylribitol phosphate polysaccharide conjugated to tetanus toxoid.

Main Article

1Current affiliation: Group Health Research Institute, Seattle, Washington, USA.

Top of Page

 

Past Issues

Select a Past Issue:

Art in Science - Selections from Emerging Infectious Diseases
Now available for order



CDC 24/7 – Saving Lives, Protecting People, Saving Money. Learn More About How CDC Works For You…

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO